Literature DB >> 32476278

The association between metabolically healthy obesity and risk of cancer: A systematic review and meta-analysis of prospective cohort studies.

Chien-Ju Lin1, Yu-Chen Chang2, Ting-Yao Cheng3, Kai Lo3, Shu-Jung Liu4, Tzu Lin Yeh1,5.   

Abstract

The risk of cancer among adults with metabolically healthy obesity (MHO) has not yet been established. We systematically searched from inception to 15 March 2020. We included prospective cohort studies that compared participants with MHO and participants with metabolically healthy non-obesity (MHNO) for incidence of any type of cancer. Benign tumors, cancer mortality or cancer prognosis were not in the scope of our analysis. The Newcastle-Ottawa Scale was used for quality assessment. Ultimately, eight studies with a total of 12 542 390 participants were included. The pooled meta-analysis using random effect model showed participants with MHO demonstrated a significantly increased risk of developing cancer (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.05 to 1.23; and I2 = 39%) than those with MHNO. The subgroup analysis revealed a higher pooled estimate (OR, 1.17; 95% CI, 1.01-1.35; and I2 = 56%) in comparison with metabolically healthy normal weight. No evidence of effect modification by age, sex, ethnicity, smoking, sample size or length of follow-up was found. In conclusion, the present study reports a positive association between MHO and cancer incidence. All individuals with obesity, even in the absence of metabolic dysfunction, should be encouraged to lose weight.
© 2020 World Obesity Federation.

Entities:  

Keywords:  cancer; malignancy; metabolically benign; metabolically health; obesity

Year:  2020        PMID: 32476278     DOI: 10.1111/obr.13049

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  6 in total

1.  Metabolic phenotypes and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies.

Authors:  Golnoosh Goodarzi; Hadis Mozaffari; Tahereh Raeisi; Fatemeh Mehravar; Bahman Razi; Maryam Lafzi Ghazi; Nazila Garousi; Shahab Alizadeh; Parisa Janmohammadi
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

Review 2.  Insulin and cancer: a tangled web.

Authors:  Brooks P Leitner; Stephan Siebel; Ngozi D Akingbesote; Xinyi Zhang; Rachel J Perry
Journal:  Biochem J       Date:  2022-03-18       Impact factor: 3.766

Review 3.  The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.

Authors:  José Antônio Fagundes Assumpção; Gabriel Pasquarelli-do-Nascimento; Mariana Saldanha Viegas Duarte; Martín Hernan Bonamino; Kelly Grace Magalhães
Journal:  J Biomed Sci       Date:  2022-02-14       Impact factor: 8.410

4.  The Association Between Metabolic Status and Risk of Cancer Among Patients With Obesity: Metabolically Healthy Obesity vs. Metabolically Unhealthy Obesity.

Authors:  Xiaonan Zheng; Ruilin Peng; Hang Xu; Tianhai Lin; Shi Qiu; Qiang Wei; Lu Yang; Jianzhong Ai
Journal:  Front Nutr       Date:  2022-02-25

5.  Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure.

Authors:  Gerd R Burmester; Peter Nash; Bruce E Sands; Kim Papp; Lori Stockert; Thomas V Jones; Huaming Tan; Ann Madsen; Hernan Valdez; Stanley B Cohen
Journal:  RMD Open       Date:  2021-05

6.  Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose.

Authors:  Stefan Grudén; Anders Forslund; Göran Alderborn; Arvid Söderhäll; Per M Hellström; Ulf Holmbäck
Journal:  Clin Pharmacol Drug Dev       Date:  2021-02-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.